NEW YORK, July 20, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb
Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Kythera
Biopharmaceuticals Inc. (NASDAQ: KYTH), and Impax Laboratories Inc.
(NASDAQ: IPXL). Free research report on Pfizer can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=PFE On
Friday, July 17, 2015, the NASDAQ
Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial
Average declined 0.19%, to finish the day at 18,086.45, and the
S&P 500 closed at 2,126.64, up 0.11%. The losses were broad
based as six out of nine sectors ended the session in negative.
Register for your complimentary reports at the links given below.
Pfizer Inc.'s stock edged 0.09% lower, to close Friday's session
at $35.07. The stock recorded a
trading volume of 16.75 million shares, below its three months
average volume of 23.07 million shares. Over the last one month and
the previous three months, Pfizer Inc.'s shares have advanced 3.21%
and 0.91%, respectively. Additionally, the stock has gained 14.52%
since the start of this year. The company's shares are trading
2.78% and 8.27% above their 50-day and 200-day moving averages,
respectively. Furthermore, Pfizer Inc.'s stock traded at a PE ratio
of 24.19 and has a Relative Strength Index (RSI) of 63.96. Sign up
and read the free notes on PFE at:
https://www.EquityResearchInstitute.com/reports?keyword=PFE
Bristol-Myers Squibb Co.'s stock finished Friday's session 0.13%
lower at $69.29. A total of 3.52
million shares were traded, which was below its three months
average volume of 6.76 million shares. Over the last one month and
the previous three months, Bristol-Myers Squibb Co.'s shares have
gained 5.09% and 6.62%, respectively. Additionally, the stock has
advanced 18.72% since the beginning of 2015. The company's shares
are trading above their 50-day and 200-day moving averages by 3.64%
and 13.07%, respectively. Bristol-Myers Squibb Co.'s stock traded
at a PE ratio of 51.33 and has an RSI of 59.66. The complimentary
notes on BMY can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=BMY
On Friday, shares in Eli Lilly and Co. ended the session 0.23%
higher at $87.37. The stock reported
a trading volume of 4.43 million shares, below its three months
average volume of 5.35 million shares. Shares of the company traded
at a PE ratio of 42.62. Eli Lilly and Co.'s shares have advanced
4.60% in the last one month, 21.39% in the previous three months
and 28.43% on YTD basis. The stock is trading 8.63% above its
50-day moving average and 21.73% above its 200-day moving average.
Moreover, shares of Eli Lilly and Co. have an RSI of 61.12.
Register for free on Equity Research Institute and access the
latest research on LLY at:
https://www.EquityResearchInstitute.com/reports?keyword=LLY
On Friday, Kythera Biopharmaceuticals Inc.'s stock edged 0.07%
lower, to close the day at $74.45.
The stock recorded a trading volume of 0.72 million shares, below
its three months average volume of 0.95 million shares. Over the
last one month and over the past three months, Kythera
Biopharmaceuticals Inc.'s shares have surged 0.46% and 52.06%,
respectively. Furthermore, the stock has rallied 114.68% since the
start of this year. The company's shares are trading 22.24% above
their 50-day moving average and 65.01% above their 200-day moving
average. Additionally, Kythera Biopharmaceuticals Inc. stock has an
RSI of 74.92. The complete research on KYTH is available for free
at:
https://www.EquityResearchInstitute.com/reports?keyword=KYTH
On Friday, shares in Impax Laboratories Inc. recorded a trading
volume of 0.45 million shares, lower than their three months
average volume of 0.79 million shares. The stock ended the day
0.62% higher at $50.42. Shares of the
company traded at a PE ratio of 80.03. Impax Laboratories Inc.'s
stock has gained 6.46% in the last one month, 0.88% in the previous
three months and 59.15% on YTD basis. The stock is trading above
its 50-day and 200-day moving averages by 7.50% and 28.66%,
respectively. Furthermore, shares of Impax Laboratories Inc. have
an RSI of 68.82. Free in-depth research on IPXL is available
at:
https://www.EquityResearchInstitute.com/reports?keyword=IPXL
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com